GRM1 and cancer: In conclusion, the combination of riluzole and sorafenib was not recommended for further broad empiric study, however, the partial response seen in a patient with metastatic pancreatic acinar cell carcinoma harboring a KANK-RAF1 fusion, accompanied by a decrease in GRM1 expression in correlative studies suggests that molecularly defined subsets of cancers may be sensitive to this combination.